Dihydromyricetin Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Mice
Diabetic cardiomyopathy (DCM) is an important cause of heart failure in diabetic patients. The present study sought to explore the potential effects of dihydromyricetin (DHM) on DCM and its possible mechanism. A diabetic model was induced by intraperitoneal injection of streptozotocin (STZ) in C57BL...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2017-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2017/3764370 |
id |
doaj-883ec7df2860496da5039aae9c88b780 |
---|---|
record_format |
Article |
spelling |
doaj-883ec7df2860496da5039aae9c88b7802020-11-25T00:29:58ZengHindawi LimitedBioMed Research International2314-61332314-61412017-01-01201710.1155/2017/37643703764370Dihydromyricetin Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic MiceBin Wu0Jie Lin1Jian Luo2Dong Han3Miaomiao Fan4Tao Guo5Ling Tao6Ming Yuan7Fu Yi8Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710032, ChinaDepartment of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710032, ChinaDepartment of Internal Medicine (VIP), The First Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang 830000, ChinaDepartment of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710032, ChinaDepartment of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710032, ChinaDepartment of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710032, ChinaDepartment of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710032, ChinaDepartment of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710032, ChinaDepartment of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710032, ChinaDiabetic cardiomyopathy (DCM) is an important cause of heart failure in diabetic patients. The present study sought to explore the potential effects of dihydromyricetin (DHM) on DCM and its possible mechanism. A diabetic model was induced by intraperitoneal injection of streptozotocin (STZ) in C57BL/6J mice. Two weeks after the STZ injection, mice were randomly allocated into the following 4 groups for treatment: the control group (CON), the control treated with DHM group (CON + DHM), the diabetes group (DM), and the diabetes treated with DHM group (DM + DHM). DHM was dissolved in distilled water and administered daily by gavage. For 14 weeks, the CON + DHM group and DM + DHM group were given a dose of 100 mg/kg/day DHM (Sigma-Aldrich), while the CON and DM groups were intragastrically given equivalent volumes of distilled water. Assessments and comparisons were made among the groups based on cardiac function and structural changes, inflammation factors, markers of oxidative stress, mitochondria function, apoptosis, and autophagy. The DHM treatment normalized body weight, preserved cardiac function, attenuated oxidative stress (MDA, SOD, and GSH-Px), reduced the levels of inflammation factors (IL-6, TNF-α), alleviated pathological changes, improved mitochondrial function (ATP content, CS activity, and complex Ι/ΙΙ/ΙΙΙ/ΙV/V activities), inhibited cardiac apoptosis, and restored autophagy in diabetic mice. DHM may have a great therapeutic potential in the treatment of DCM.http://dx.doi.org/10.1155/2017/3764370 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bin Wu Jie Lin Jian Luo Dong Han Miaomiao Fan Tao Guo Ling Tao Ming Yuan Fu Yi |
spellingShingle |
Bin Wu Jie Lin Jian Luo Dong Han Miaomiao Fan Tao Guo Ling Tao Ming Yuan Fu Yi Dihydromyricetin Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Mice BioMed Research International |
author_facet |
Bin Wu Jie Lin Jian Luo Dong Han Miaomiao Fan Tao Guo Ling Tao Ming Yuan Fu Yi |
author_sort |
Bin Wu |
title |
Dihydromyricetin Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Mice |
title_short |
Dihydromyricetin Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Mice |
title_full |
Dihydromyricetin Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Mice |
title_fullStr |
Dihydromyricetin Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Mice |
title_full_unstemmed |
Dihydromyricetin Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Mice |
title_sort |
dihydromyricetin protects against diabetic cardiomyopathy in streptozotocin-induced diabetic mice |
publisher |
Hindawi Limited |
series |
BioMed Research International |
issn |
2314-6133 2314-6141 |
publishDate |
2017-01-01 |
description |
Diabetic cardiomyopathy (DCM) is an important cause of heart failure in diabetic patients. The present study sought to explore the potential effects of dihydromyricetin (DHM) on DCM and its possible mechanism. A diabetic model was induced by intraperitoneal injection of streptozotocin (STZ) in C57BL/6J mice. Two weeks after the STZ injection, mice were randomly allocated into the following 4 groups for treatment: the control group (CON), the control treated with DHM group (CON + DHM), the diabetes group (DM), and the diabetes treated with DHM group (DM + DHM). DHM was dissolved in distilled water and administered daily by gavage. For 14 weeks, the CON + DHM group and DM + DHM group were given a dose of 100 mg/kg/day DHM (Sigma-Aldrich), while the CON and DM groups were intragastrically given equivalent volumes of distilled water. Assessments and comparisons were made among the groups based on cardiac function and structural changes, inflammation factors, markers of oxidative stress, mitochondria function, apoptosis, and autophagy. The DHM treatment normalized body weight, preserved cardiac function, attenuated oxidative stress (MDA, SOD, and GSH-Px), reduced the levels of inflammation factors (IL-6, TNF-α), alleviated pathological changes, improved mitochondrial function (ATP content, CS activity, and complex Ι/ΙΙ/ΙΙΙ/ΙV/V activities), inhibited cardiac apoptosis, and restored autophagy in diabetic mice. DHM may have a great therapeutic potential in the treatment of DCM. |
url |
http://dx.doi.org/10.1155/2017/3764370 |
work_keys_str_mv |
AT binwu dihydromyricetinprotectsagainstdiabeticcardiomyopathyinstreptozotocininduceddiabeticmice AT jielin dihydromyricetinprotectsagainstdiabeticcardiomyopathyinstreptozotocininduceddiabeticmice AT jianluo dihydromyricetinprotectsagainstdiabeticcardiomyopathyinstreptozotocininduceddiabeticmice AT donghan dihydromyricetinprotectsagainstdiabeticcardiomyopathyinstreptozotocininduceddiabeticmice AT miaomiaofan dihydromyricetinprotectsagainstdiabeticcardiomyopathyinstreptozotocininduceddiabeticmice AT taoguo dihydromyricetinprotectsagainstdiabeticcardiomyopathyinstreptozotocininduceddiabeticmice AT lingtao dihydromyricetinprotectsagainstdiabeticcardiomyopathyinstreptozotocininduceddiabeticmice AT mingyuan dihydromyricetinprotectsagainstdiabeticcardiomyopathyinstreptozotocininduceddiabeticmice AT fuyi dihydromyricetinprotectsagainstdiabeticcardiomyopathyinstreptozotocininduceddiabeticmice |
_version_ |
1725328698366754816 |